Partner Headlines - ARNA

  1. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  2. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  3. Earnings Scheduled For August 1, 2014

    Benzinga
  4. Benzinga's Top #PreMarket Losers

    Benzinga
  5. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  6. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  7. Benzinga's Top #PreMarket Losers

    Benzinga
  8. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  9. FDA delays Orexigen drug

    IBD
  10. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  11. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  12. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  13. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  14. Earnings Scheduled For May 12, 2014

    Benzinga
  15. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  16. Benzinga's Top #PreMarket Losers

    Benzinga
  17. Earnings Scheduled For February 27, 2014

    Benzinga
  18. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  19. Top Trending Tickers On StockTwits For February 14

    Benzinga
  20. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  21. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  22. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  23. The Top Five Drug Launches Of 2013

    IBD
  24. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  25. Benzinga's Top #PreMarket Gainers

    Benzinga
  26. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  27. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  28. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  29. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  30. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  31. Benzinga's Top #PreMarket Losers

    Benzinga
  32. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  33. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  34. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  35. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  36. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  37. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  38. Benzinga's Top Pre-Market Losers

    Benzinga
  39. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  40. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  41. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  42. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  43. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  44. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  45. Stocks Hitting 52-Week Lows

    Benzinga
  46. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  47. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  48. Stocks Hitting 52-Week Lows

    Benzinga
  49. Stocks Hitting 52-Week Lows

    Benzinga
  50. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  51. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  52. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  53. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  54. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  55. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  56. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  57. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  58. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  59. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  60. Vivus fell 4.2% to 13.72

    IBD
  61. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  62. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  63. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  64. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  65. Benzinga's Top Pre-Market Gainers

    Benzinga
  66. The Best Small Cap Performers of 2012

    Benzinga
  67. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  68. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  69. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  70. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  71. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  72. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  73. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  74. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
  75. Arena Pharmaceuticals Initiates Phase 1 Multiple Dose Clinical ...

    Benzinga
  76. WEEKLY CFO SELLS HIGHLIGHT: QCOM, RA, ARNA, ATU, DGX, MSCC

    GuruFocus
  77. Who Needs Diet and Exercise? Health Plans Cover New Vivus Obesity ...

    YCharts
  78. Vivus Expects EU To Reject Diet Drug, Shares Fall

    IBD
  79. Vivus Dives 11% After Warning EU May Not Back Obesity Drug

    FoxBusiness
  80. Stocks Finish Little Changed with Yahoo (YHOO) and FedEx (FDX) ...

    MarketIntelligenceCenter
  81. All Eyes On Vivus As Weight Loss Drug Hits Market

    YCharts
  82. Short Sellers Shy Away from Biotech Firms

    Benzinga
  83. Benzinga's Top Pre-Market Gainers

    Benzinga
  84. UPDATE: Credit Suisse Initiates Arena Pharmaceuticals at Underperform ...

    Benzinga
  85. Health Care Sector Wrap

    FoxBusiness
  86. Short Interest in Biotech Firms on the Rise

    Benzinga
  87. What Slims Down Fastest After Diet Drugs Are Approved by he FDA? ...

    YCharts
  88. Health Care Sector Wrap

    FoxBusiness
  89. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  90. Four Investment Options Presented by Obesity and Related Health ...

    YCharts
  91. Biotechs In Motion As New Drug Pipeline Brims

    IBD
  92. Who's Next Facebook? VCs Try Software, Internet Firms

    IBD
  93. Arena Pharmaceuticals (ARNA) Falls 8.3% After Rival Weight Loss ...

    MarketIntelligenceCenter
  94. Wednesday Market Movers

    Benzinga
  95. Vivus Stock Jumps 12.5% On Drug Approval

    IBD
  96. Benzinga's Top Pre-Market Losers

    Benzinga
  97. Drug Stocks Up On Glaxo, Par M&A And Gilead HIV Pill

    IBD
  98. Vivus Rises Ahead Of FDA Vote On Qnexa Diet Drug

    IBD
  99. Stocks Move Lower as Euro Zone and Earnings Worries Persist with ...

    MarketIntelligenceCenter
  100. Dendreon, Pharmacyclics and Other Biotech Takeover Targets

    Benzinga
Trading Center